All In Biotech

Drug Trial Radar · NCT04103450

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Last checked: Nov 20, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

276

Actual

Start

Sep 19, 2019

Primary completion

Jul 29, 2022

Study completion Jul 29, 2022

Sponsor

Lead sponsor
Urovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Sep 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).

Conditions

  • Overactive Bladder

Interventions

  • VibegronDrug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%)Time frame: Up to Week 52
  2. Number of Participants With Clinically Significant Changes in Hematology ParametersTime frame: Up to Week 52
  3. Number of Participants With Clinically Significant Changes in Chemistry ParametersTime frame: Up to Week 52
  4. Number of Participants With Clinically Significant Changes in Urinary ParametersTime frame: Up to Week 52
  5. Number of Participants With Clinically Significant Changes in Coagulation ParameterTime frame: Up to Week 52
  6. Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)Time frame: Baseline; Week 52
  7. Change From Baseline in Heart RateTime frame: Baseline; Week 52

Locations

35 sites in 2 countries. Site status is shown where the registry gives one.

  • Private Practice

    Huntsville, Alabama

  • Clinical Trials Research

    Lincoln, California

  • American Institute of Research

    Los Angeles, California

  • Tri Valley Urology Medical Group

    Murrieta, California

  • Northern California Research Corp

    Sacramento, California

  • San Diego Clinical Trials

    San Diego, California

  • Skyline Urology

    Torrance, California

  • Imagine Research of Palm Beach County - Urology

    Boynton Beach, Florida

  • Tampa Bay Medical Research

    Clearwater, Florida

  • Quantum Clinical Trials

    Miami, Florida

  • Urology Center Of Florida

    Pompano Beach, Florida

  • Precision Clinical Research

    Sunrise, Florida

  • Clinical Research of Central Florida

    Winter Haven, Florida

  • DelRicht Research

    New Orleans, Louisiana

  • Regional Urology, LLC

    Shreveport, Louisiana

  • Boston Clinical Trials Inc - Urology

    Boston, Massachusetts

  • Bay State Clinical Trials, Inc.

    Watertown, Massachusetts

  • Beaumont Hospital Royal Oak - Urology Research

    Royal Oak, Michigan

  • CentraCare Clinic - Adult & Pediatric Urology

    Sartell, Minnesota

  • Poplar Bluff Urology

    Poplar Bluff, Missouri

  • Adult & Pediatric Urology P.C. - Urology

    Omaha, Nebraska

  • Excel Clinical Research - Internal Medicine

    Las Vegas, Nevada

  • Private Practice

    Las Vegas, Nevada

  • Premier Urology Group, LLC

    Edison, New Jersey

  • New Jersey Urology NJU

    Englewood, New Jersey

  • AccuMed Research Associates

    Garden City, New York

  • Urological Surgeons of Long Island

    Garden City, New York

  • Clinical Research Solutions

    Middleburg Heights, Ohio

  • Advances In Health, Inc.

    Houston, Texas

  • Wasatch Clinical Research LLC

    Salt Lake City, Utah

  • Seattle Urology Research Center

    Burien, Washington

  • Centrum Medyczne Linden

    Krakow, Poland

  • Centrum Medyczne PROMED

    Krakow, Poland

  • Medicome Sp. z o.o.

    Oświęcim, Poland

  • Nzoz Heureka

    Piaseczno, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.